A Phase I/II Study of Bevacizumab and Erlotinib in Combination With Docetaxel and Prednisone for Patients With Hormone Refractory Prostate Cancer.

Trial Profile

A Phase I/II Study of Bevacizumab and Erlotinib in Combination With Docetaxel and Prednisone for Patients With Hormone Refractory Prostate Cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 30 Mar 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Docetaxel; Prednisone
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Apr 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 23 Oct 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top